ArticleThe journal of headache and pain2022

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.

Hannah Schenk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.